NEW ORLEANS — After 5 years of follow-up, eyes that received the Hydrus microstent for mild to moderate glaucoma required fewer medications and surgeries compared with eyes that underwent cataract surgery alone, according to a study.
“This is a continuous follow-up, which I think is important, and we had over 80% of patients that made that follow-up visit,” Ike K. Ahmed, MD, said during a presentation at the American Academy of Ophthalmology meeting.
After phacoemulsification, 556 eyes were randomly assigned to receive the Hydrus microstent (Ivantis) or no additional